We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Life Science Reit Plc | LABS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.50 | 1.29% | 39.20 | 16:35:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 38.70 | 38.70 | 39.70 | 39.20 | 38.70 |
| Industry Sector |
|---|
| REAL ESTATE INVESTMENT TRUSTS |
| Top Posts |
|---|
Posted at 17/4/2023 07:10 by gbcol To partly answer my own question, they have today announced a Capital Markets Day for institutional investors and analysts, taking place tomorrow, Tuesday 18 April 2023. |
Posted at 14/4/2023 10:23 by gbcol Chrisdgb, I haven’t picked up on any upcoming investor events for LABS, have you got any details? TIA.For good or bad (and it’s not good ATM), I’ve got a fairly substantial holding in LABS now. Next month’s divi is going to be very decent though. |
Posted at 12/4/2023 11:40 by chrisdgb Couple of investor events coming up in the next few weeks, hopefully generate some interest. |
Posted at 17/7/2022 18:07 by saltwood I bought shortly after the IPO and intend to be a long-term investor. Three ideas I have for the recent weakness are:a) We do not have an updated NAV post December 2021. I would expect an uplift but we simply do not know. Ditto on the dividend. b) The strategy seems to depend to a large extent on asset management - ie redevelopment, repurposing existing buildings and, in the case of the Oxford Business Park, construction and development. I imagine inflation of 9%+ will be unkind in these circumstances so costs may be increasing beyond that anticipated. c) Some governance concerns were flagged at the time of the results - I believe this to be a one off issue but clearly concerns about corporate governance destroy value. There are other questions too - for example, the company is fully invested yet has a pipeline of acquisition targets. What is the growth strategy from here? I hope these ideas help. As I say I am very positive on the long term outlook and pleased to hold - indeed, will probably top up at these levels. |
Posted at 18/11/2021 22:11 by bountyhunter "Midas verdict: Britain has long been at the forefront of scientific and medical research but the pandemic has shown how vital this sector is and how much support it needs. Life Science REIT will provide operators with the space to do their best work and the shares should deliver attractive returns as well. At £1, the shares are a buy." |
Posted at 18/11/2021 22:11 by bountyhunter A promising ReitConsider also Life Science Reit, a real-estate investment trust. It plans to list on Aim and raise £300m to invest in laboratories, offices and co-working spaces, manufacturing and testing facilities, and data centres. It will then rent these out. Life-sciences research is a burgeoning sector. The fund will exclusively focus on the “golden triangle”, which comprises research-intensive universities in Cambridge, Oxford and London. The fund targets income-producing assets with a yearly NAV total return above 10% and an initial yearly dividend yield of 4%, set to grow to 5% in the early years. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
